Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVX

Vilga Financial Planning LLC acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 22,000 shares of the company’s stock, valued at approximately $2,178,000. Abivax comprises about 1.3% of Vilga Financial Planning LLC’s portfolio, making the stock its 21st largest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Eversept Partners LP raised its position in Abivax by 42.0% during the first quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock valued at $104,048,000 after purchasing an additional 276,589 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Abivax by 31.6% during the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after purchasing an additional 211,068 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Abivax by 152.4% during the 4th quarter. Lord Abbett & CO. LLC now owns 849,732 shares of the company’s stock valued at $114,591,000 after buying an additional 513,026 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Abivax by 40.9% during the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock valued at $81,923,000 after buying an additional 213,440 shares in the last quarter. Finally, Two Seas Capital LP bought a new stake in Abivax in the 3rd quarter worth approximately $66,996,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $89.05 on Friday. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of -14.69 and a beta of 1.14. The business has a 50-day simple moving average of $111.22 and a two-hundred day simple moving average of $115.50. Abivax SA Sponsored ADR has a fifty-two week low of $69.81 and a fifty-two week high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The firm had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, research analysts predict that Abivax SA Sponsored ADR will post -4.18 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wedbush lowered their price target on shares of Abivax from $140.00 to $118.00 and set a “neutral” rating for the company in a research note on Tuesday, September 22nd. Leerink Partners raised their price objective on Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Piper Sandler increased their target price on Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, The Goldman Sachs Group initiated coverage on Abivax in a research report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and an average target price of $156.69.

Abivax Company Profile

Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. The company’s lead investigational product is obefazimod, an oral small-molecule treatment being developed for ulcerative colitis, a chronic inflammatory disease of the colon.

Obefazimod, formerly known as ABX464, is designed to increase levels of microRNA-124, a molecule involved in regulating inflammatory responses. Abivax is evaluating the therapy in late-stage clinical studies for ulcerative colitis and has also investigated its potential in other inflammatory conditions, including Crohn’s disease.

Founded in 2013 and headquartered in Paris, France, Abivax conducts its development activities through international clinical programs and serves the global biopharmaceutical market.